title: Prognostic factors of liver metastases from uveal melanoma.
abstract: OBJECTIVE
  This study was designed to assess survival and identify prognostic factors for liver metastases diagnosed by systematic screening in uveal melanoma patients.
  
  
  METHODS
  Among 602 consecutive patients treated over 10 years for uveal melanoma and followed by systematic semi-annual hepatic screening (abdominal ultrasonography), 63 (10.5%) developed liver metastases; these patients form the basis of this study. Factors including patient demographics, characteristics of the uveal tumor, metastasis-free interval, severity of liver metastatic involvement, and treatments of metastases were studied retrospectively regarding their prognostic value, using univariate (Kaplan-Meier method) and multivariate (Cox model) analyses.
  
  
  RESULTS
  Thirty-five patients (55.6% of the metastatic population) received systemic chemotherapy or best supportive care only; 14 patients (22.2% of the metastatic population) diagnosed with diffuse liver involvement had cytoreductive surgery and intra-arterial chemotherapy; 14 (22.2% of the metastatic population) had complete surgical removal of liver metastases followed by postoperative intra-arterial chemotherapy. No significant surgical complications were experienced. The median overall survival after diagnosis of liver metastases was 15 months. It reached 25 months for selected patients with complete resection (P=0.0002). In this cohort of 63 patients, ten or fewer preoperatively diagnosed metastases and primary uveal melanoma not involving the ciliary body were independently associated with better prognosis.
  
  
  CONCLUSIONS
  This study suggests that selected patients with screened liver metastases from uveal melanoma may benefit from aggressive treatment, including surgery. The two independent favorable prognostic factors are fewer than ten metastases at screening and the absence of ciliary body involvement.
authors.affiliation: Department of Ophthalmology, Croix-Rousse Hospital, 103, Grande rue de la Croix-Rousse, Lyon, 69004, France. kodjikian.laurent@wanadoo.fr
authors.forename: Laurent
authors.initials: L
authors.lastname: Kodjikian
authors.forename: Jean-Daniel
authors.initials: JD
authors.lastname: Grange
authors.forename: Stéphano
authors.initials: S
authors.lastname: Baldo
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Baillif
authors.forename: Justus G
authors.initials: JG
authors.lastname: Garweg
authors.forename: Michel
authors.initials: M
authors.lastname: Rivoire
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014604:Uveal Neoplasms / Q000401:mortality / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents